# US 2011/0086862 A1 · Polymorphs of pardoprunox

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0086862 A1
- Document ID: US20110086862A1
- Status: Published application
- Kind: A1
- Application number: 12/901,542
- Filed: 2010-10-10
- Published: 2011-04-14
- Earliest claimed: 2009-10-12
- Inventors: Jeroen Van Rheenen; Wilhelmus G.H.M. Muijselaar; Hendrik Teunissen
- Web page: https://patentgrep.com/patent/US20110086862A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 263/58: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention relates to a process for the preparation of 7-(4-methyl-1-piperazinyl)benzoxazol-2(3H)-one hydrochloride, a partial dopamine-D2 receptor agonist and a full serotonin 5-HT1A receptor agonist. 7-(4-methyl-1-piperazinyl)benzoxazol-2(3H)-one hydrochloride The invention also relates to polymorphic forms of said compound, as well as to pharmaceutical compositions containing these compounds, to methods for preparing the compounds, to methods for preparing intermediates useful for their synthesis, and to methods for preparing compositions containing these compounds. The invention also relates to the use of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in conditions or diseases of the central nervous system, caused by disturbances of the dopaminergic and/or serotonergic systems, for example: anxiety disorders (including generalized anxiety, panic disorder and obsessive compulsive disorder), depression, autism, schizophrenia, Parkinson's disease, restless leg syndrome, and disturbances of cognition and memory.

## Claims

### Claim 1

The α-polymorph of 7-[(4-methyl)-1-piperazinyl]-2(3H)-benzoxazolone hydrochloride, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic reflexes, expressed in degrees of diffraction angle 2 θ, at about: 17.4, 21.5, 23.3, and 28.8, an infrared spectrum recorded in Attenuated Total Reflectance having characteristic absorption bands expressed in reciprocal centimeters at about: 2454 and 1604, and a Raman spectrum having characteristic absorption bands expressed in reciprocal centimeters at about: 3079, 3031 and 1632.

### Claim 2 (depends on 1)

The polymorph claimed in claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic reflexes, expressed in degrees of diffraction angle 2 θ, at about: 15.3, 17.4, 18.4, 20.1, 20.9, 21.5, 23.3, 23.6, 25.4, and 28.8, an infrared spectrum recorded in Attenuated Total Reflectance having characteristic absorption bands expressed in reciprocal centimeters at about: 2454, 1749, 1632, 1604, 1456, 1394, 1265, 1144, 947, and 735, and a Raman spectrum having characteristic absorption bands expressed in reciprocal centimeters at about: 3079, 3031, 2987, 2972, 1632, 1262, 859, 561, 499, and 273.

### Claim 3

A pharmaceutical composition comprising, in addition to a pharmaceutically acceptable carrier and at least one pharmaceutically acceptable auxiliary substance, a pharmacologically active amount of the α-polymorph of 7-[(4-methyl)-1-piperazinyl]-2(3H)-benzoxazolone hydrochloride, as an active ingredient, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic reflexes, expressed in degrees of diffraction angle 2 θ, at about: 17.4, 21.5, 23.3, and 28.8, an infrared spectrum recorded in Attenuated Total Reflectance having characteristic absorption bands expressed in reciprocal centimeters at about: 2454 and 1604, and a Raman spectrum having characteristic absorption bands expressed in reciprocal centimeters at about: 3079, 3031 and 1632.

### Claim 4 (depends on 3)

The pharmaceutical composition as claimed in claim 3, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic reflexes, expressed in degrees of diffraction angle 2 θ, at about: 15.3, 17.4, 18.4, 20.1, 20.9, 21.5, 23.3, 23.6, 25.4, and 28.8, an infrared spectrum recorded in Attenuated Total Reflectance having characteristic absorption bands expressed in reciprocal centimeters at about: 2454, 1749, 1632, 1604, 1456, 1394, 1265, 1144, 947, and 735, and a Raman spectrum having characteristic absorption bands expressed in reciprocal centimeters at about: 3079, 3031, 2987, 2972, 1632, 1262, 859, 561, 499, and 273.

### Claim 5

A method for treating at least one central nervous system disorder chosen from anxiety disorders, depression, autism, schizophrenia, Parkinson's disease, restless leg syndrome, and disturbances of cognition and memory, the method comprising administering a pharmaceutical composition to a patient in need thereof, said composition comprising the α-polymorph of 7-[(4-methyl)-1-piperazinyl]-2(3H)-benzoxazolone hydrochloride, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic reflexes, expressed in degrees of diffraction angle 2 θ, at about: 17.4, 21.5, 23.3, and 28.8, an infrared spectrum recorded in Attenuated Total Reflectance having characteristic absorption bands expressed in reciprocal centimeters at about: 2454 and 1604, and a Raman spectrum having characteristic absorption bands expressed in reciprocal centimeters at about: 3079, 3031 and 1632.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic reflexes, expressed in degrees of diffraction angle 2 θ, at about: 15.3, 17.4, 18.4, 20.1, 20.9, 21.5, 23.3, 23.6, 25.4, and 28.8, an infrared spectrum recorded in Attenuated Total Reflectance having characteristic absorption bands expressed in reciprocal centimeters at about: 2454, 1749, 1632, 1604, 1456, 1394, 1265, 1144, 947, and 735, and a Raman spectrum having characteristic absorption bands expressed in reciprocal centimeters at about: 3079, 3031, 2987, 2972, 1632, 1262, 859, 561, 499, and 273.

### Claim 7

A method for preparing an α-polymorph of 7-[(4-methyl)-1-piperazinyl]-2(3H)-benzoxazolone hydrochloride, comprising:
(i) dissolving 7-[(4-methyl)-1-piperazinyl]-2(3H)-benzoxazolone (5) in a mixture of a polar solvent and water;
(ii) adding HCl; and
(iii) isolating the product as a crystalline product.

### Claim 8 (depends on 7)

The method as claimed in claim 7, wherein said polar solvent is chosen from acetonitrile, methyl ethyl ketone, and isopropylalcohol.

### Claim 9 (depends on 8)

The method as claimed in claim 8, wherein the polar solvent is acetonitrile.

### Claim 10 (depends on 7)

The method as claimed in claim 7, wherein said mixture comprises from 10% (w/w) to 30% (w/w) water.

### Claim 11 (depends on 7)

The method as claimed in claim 7, wherein from 1.05 to 1.45 equivalents of HCl is added in step (ii).

### Claim 12 (depends on 11)

The method as claimed in claim 11, wherein the HCl is in the form of 36% hydrochloric acid in water.
